Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Oncotarget

Volumn 7, Issue 35, 2016, Pages 56491-56500

  Radovich, Milan ^a,b   Kiel, Patrick J ^a,b   Nance, Stacy M ^a   Niland, Erin E ^a   Parsley, Megan E ^a   Ferguson, Meagan E ^a   Jiang, Guanglong ^b   Ammakkanavar, Natraj R ^b   Einhorn, Lawrence H ^b   Cheng, Liang ^b   Nassiri, Mehdi ^b   Davidson, Darrell D ^b   Rushing, Daniel A ^b   Loehrer, Patrick J ^b   Pili, Roberto ^b   Hanna, Nasser ^b   Thomas Callaghan, J ^b   Skaar, Todd C ^b   Helft, Paul R ^b   Shahda, Safi ^b   O'Neil, Bert H ^b   Schneider, Bryan P ^a,b   more..

^a INDIANA UNIVERSITY HEALTH   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genomics; Next generation sequencing; Personalized medicine; Precision medicine

Indexed keywords

ADULT; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENOMICALLY GUIDED THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; RNA SEQUENCE; AGED; BREAST TUMOR; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; INDIANA; METHODOLOGY; MIDDLE AGED; NEOPLASM; ONCOLOGY; PANCREAS TUMOR; PROCEDURES; SARCOMA; SOFT TISSUE TUMOR; TREATMENT OUTCOME; UNIVERSITY;

ANTINEOPLASTIC AGENT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIANA; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PANCREATIC NEOPLASMS; PRECISION MEDICINE; RESEARCH DESIGN; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; UNIVERSITIES;

EID: 84984906761     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10606     Document Type: Article

References (26)

1. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Science translational medicine. 2011; 3:111ra121.
2. Garraway LA, Verweij J and Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013; 31:1803-1805.
3. Collins FS and Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372:793-795.
4. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, Lawrence M, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014; 20:682-688.
5. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD and Luthra R. Clinical validation of a nextgeneration sequencing screen for mutational hotspots in 46 cancer-related genes. The Journal of molecular diagnostics: JMD. 2013; 15:607-622.
6. Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015; 17:385-399.
7. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502:333-339.
8. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M and Garraway LA. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011; 29:3085-3096.
9. Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014; 371:1426-1433.
10. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014; 4:546-553.
11. Von HoffDD, Stephenson JJ, Jr., Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010; 28:4877-4883.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-1672.
13. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673-1684.
14. Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI and Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol. 2015; 1:778-84. doi: 10.1001/jamaoncol.2015.2378.
15. Longley DB and Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005; 205:275-292.
16. Agrawal M and Emanuel EJ. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA. 2003; 290:1075-1082.
17. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, RuschoffJ and Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687-697.
18. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P and Hirsh V. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-smallcell lung cancer. Annals of oncology. 2004; 15:19-27.
19. Ashworth A, Lord CJ and Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell. 2011; 145:30-38.
20. Le Tourneau C, Paoletti X, Servant N, Bieche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer. 2014; 111:17-24.
21. Barker AD, Sigman CC, KelloffGJ, Hylton NM, Berry DA and Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical pharmacology and therapeutics. 2009; 86:97-100.
22. McNeil C. NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst. 2015; 107.
23. Parker BA, Schwaederle MC, Schwab RB, Daniels GA, Piccioni DE, Helsten TL, Bazhenova L, Fanta PT, Lippman SM and Kurzrock R. Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience. Journal of Clinical Oncology: 2015 ASCO Annual Meeting Abstract. 2015; 33.
24. Wheler JJ, Yelensky R, Stephen B, Hong DS, Zinner R, Subbiah V, Fu SQ, Karp DD, Falchook GS, Naing A, Tsimberidou AM, Piha-Paul SA, Janku F, Li YL, Lee JJ, Miller VA, et al. Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. Journal of Clinical Oncology: 2015 ASCO Annual Meeting Abstract. 2015; 33.
25. Cobain EF, Robinson DR, Wu YM, Worden FP, Smith DC, Schuetze S, Chugh R, Ramnath N, Schott AF, Hayes DF, Chinnaiyan AM and Talpaz M. Clinical impact of highthroughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center. Journal of Clinical Oncology: 2015 ASCO Annual Meeting Abstract. 2015; 33.
26. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31:1023-1031.